New Drug Development in Hematology
The procedure of bringing new therapeutic medicines for the treatment of damage into the commercial centre is a time-consuming and expensive one. When everything is said and done, the most recent techniques for tranquillize disclosure are selected. Medication repurposing asserts the ability to quickly introduce fresh restorative strategies into clinical trials with minimal effort. By employing their known toxicological, pharmacology, and pharmacokinetics, identified on-patent or off-patent drugs with undiscovered anticancer movement can be quickly first in class into clinical testing for this unique indicator. Pedantic assembling can take a look at the medicine confession sector in this way, and smaller biotechnology companies can "de-risk" early-stage placid declaration projects. Some inferential techniques for identifying sedate repurposing opportunities are highlighted in this article, with a focus on hematopoietic malignancies.
- Ruxolitinib
- Acalabrutinib
Related Conference of New Drug Development in Hematology
New Drug Development in Hematology Conference Speakers
Recommended Sessions
- Blood Based Products
- Blood Disease Condition and Treatment
- Blood Oncology
- Blood Transplantation, Thrombosis and Hemostasis
- Case Reports and Epidemiology
- Diagnosis in Blood Disorder
- Hematologic Oncology
- Hematological Disorders
- Hematology and Pharma Industry
- Hematology and Stem Cell Research
- Hematology Market
- Hematology Nursing
- Immunology
- New Drug Development in Haematology
- New Drug Development in Hematology
- Pediatric Hematology
- Transfusion Medicine and Haematology Research
- Various Aspects of Hematology
Related Journals
Are you interested in
- Advances in Hematologic Malignancies - Blood Disorders 2025 (Italy)
- Advances in Hemostasis and Thrombosis - Blood Disorders 2025 (Italy)
- Biomarkers in Hematology and Oncology - Hematology Congress 2025 (Switzerland)
- Blood Disorders and the Immune System - Blood Disorders 2025 (Italy)
- Blood Disorders Diagnosis & Treatment - HEMATOLOGY 2025 (Spain)
- Blood Disorders in Aging Populations - Blood Disorders 2025 (Italy)
- Blood Disorders: Diagnosis and Treatment - Hematology Congress 2025 (Switzerland)
- Blood Transfusion - HEMATOLOGY 2025 (Spain)
- Cancer Genomics & Metabolomics - Hematology Congress 2025 (Switzerland)
- Case Reports in Hematology - Hematology Congress 2025 (Switzerland)
- Case reports of Hematology - HEMATOLOGY 2025 (Spain)
- CellTherapy - HEMATOLOGY 2025 (Spain)
- Clinical Haematology - Hematology Congress 2025 (Switzerland)
- Cord Blood Transplantation - Hematology Congress 2025 (Switzerland)
- COVID-19 and Hematology - HEMATOLOGY 2025 (Spain)
- Cutting-Edge Research in Blood Disorders - Blood Disorders 2025 (Italy)
- Digital Imaging in Hematology - Hematology Congress 2025 (Switzerland)
- Disorders of Vascular Bleeding - HEMATOLOGY 2025 (Spain)
- Future Trends in Hematology: Artificial Intelligence and Big Data - Blood Disorders 2025 (Italy)
- Gene Therapy and Genetic Engineering in Hematology - Blood Disorders 2025 (Italy)
- Haematology and Pharma Industry - Hematology Congress 2025 (Switzerland)
- Hematologic Cancers - Hematology Congress 2025 (Switzerland)
- Hematologic Toxicities and Side Effects of Cancer Therapy - Blood Disorders 2025 (Italy)
- Hematology - HEMATOLOGY 2025 (Spain)
- Hematology and Cardio-Oncology - Hematology Congress 2025 (Switzerland)
- Hematology in Global Health: Addressing Disparities - Blood Disorders 2025 (Italy)
- Hematology Nursing - Hematology Congress 2025 (Switzerland)
- Hematology Oncology - HEMATOLOGY 2025 (Spain)
- Hematology: Diagnostics and Screening - Hematology Congress 2025 (Switzerland)
- Hematopoietic Malignancies - Hematology Congress 2025 (Switzerland)
- Immunohematology - Hematology Congress 2025 (Switzerland)
- Immunohematology - HEMATOLOGY 2025 (Spain)
- Immunotherapy and Cellular Therapies in Hematology - Blood Disorders 2025 (Italy)
- Innovations in Red Blood Cell Disorders - Blood Disorders 2025 (Italy)
- Leukaemia and Lymphoma - HEMATOLOGY 2025 (Spain)
- Multiple Myeloma, Amyloidosis, and Stem Cell Transplantation - HEMATOLOGY 2025 (Spain)
- Neuro-Hematology - Hematology Congress 2025 (Switzerland)
- New Drug Development in Hematology - HEMATOLOGY 2025 (Spain)
- Novel Diagnostic Techniques and Biomarkers in Hematology - Blood Disorders 2025 (Italy)
- Organ Specific Cancer - Hematology Congress 2025 (Switzerland)
- Patient Blood Management - HEMATOLOGY 2025 (Spain)
- Pediatric Hematology - HEMATOLOGY 2025 (Spain)
- Pediatric Hematology - Hematology Congress 2025 (Switzerland)
- Pediatric Hematology: Challenges and Innovations - Blood Disorders 2025 (Italy)
- Stem Cell Research - HEMATOLOGY 2025 (Spain)
- Stem Cell Therapy - Hematology Congress 2025 (Switzerland)
- Stem Cell Transplantation and Regenerative Medicine - Blood Disorders 2025 (Italy)
- Thalassemia - HEMATOLOGY 2025 (Spain)
- Therapeutic Apheresis - HEMATOLOGY 2025 (Spain)
- Thrombosis and Coagulation - HEMATOLOGY 2025 (Spain)
- Transfusion Medicine - HEMATOLOGY 2025 (Spain)
- Transfusion Medicine: Advances and Challenge - Blood Disorders 2025 (Italy)
- Transfusion Medicines - Hematology Congress 2025 (Switzerland)
- Transfusion Transmissible Infections - HEMATOLOGY 2025 (Spain)
- Vascular Bleeding Disorders - Hematology Congress 2025 (Switzerland)